

September 27, 2019

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
Scrip code: STAR

Dear Sirs,

**Sub: Further Updates on Ranitidine Tablets for the US Markets**

As advised in our earlier notification to the Stock Exchanges on September 25, 2019, Strides has received an Information Request (IR) from the USFDA to provide test data related to N-nitrosodimethylamine (NDMA) impurities in Ranitidine tablets. This data is to be provided to the agency in 30 days.

While the Company conducts the relevant tests mandated by the USFDA, it has suspended sales of ranitidine tablets in the US market until such time it has clarity of next steps as would be indicated by the USFDA.

The Company predominantly sells Ranitidine tablets in the US markets, and its front end sales globally for the product were ~US\$ 9 million in H1FY20.

In spite of this temporary suspension of the ranitidine supplies, the Company retains its FY20 growth outlook for the US markets.

You are requested to take the same on record.

Thanks & Regards,

**For Strides Pharma Science Limited**



**Manjula Ramamurthy**  
Company Secretary



**Strides Pharma Science Limited**

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India

Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India

Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

info@strides.com; www.strides.com